share_log

Wells Fargo Assumes Alaunos Therapeutics at Overweight, Announces Price Target of $3

Benzinga Real-time News ·  Oct 4, 2022 07:48

Wells Fargo analyst Nick Abbott assumes Alaunos Therapeutics (NASDAQ:TCRT) with a Overweight rating and announces Price Target of $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment